Glaucoma is a potentially blinding condition for which multiple treatment options are available to slow or halt progression of the disease. However, many of these treatment options increase the risk of glaucoma therapy-related ocular surface disease (GTR-OSD). Dry eye disease (DED) is a significant ocular comorbidity affecting 40-60% of glaucoma patients worldwide¹. Glaucoma has been identified as a significant risk factor for DED with an odds ratio of 1.77 (95% CI: 1.17 - 2.69) in a large meta-analysis².
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
